Literature DB >> 15829979

Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma.

Peter S White1, Patricia M Thompson, Takahiro Gotoh, Erin R Okawa, Jun Igarashi, Marleen Kok, Cynthia Winter, Simon G Gregory, Michael D Hogarty, John M Maris, Garrett M Brodeur.   

Abstract

Substantial genomic and functional evidence from primary tumors and cell lines indicates that a consistent region of distal chromosome 1p is deleted in a sizable proportion of human neuroblastomas, suggesting that this region contains one or more tumor suppressor genes. To determine systematically and precisely the location and extent of 1p deletion in neuroblastomas, we performed allelic loss studies of 737 primary neuroblastomas and genotype analysis of 46 neuroblastoma cell lines. Together, the results defined a single region within 1p36.3 that was consistently deleted in 25% of tumors and 87% of cell lines. Two neuroblastoma patients had constitutional deletions of distal 1p36 that overlapped the tumor-defined region. The tumor- and constitutionally-derived deletions together defined a smallest region of consistent deletion (SRD) between D1S2795 and D1S253. The 1p36.3 SRD was deleted in all but one of the 184 tumors with 1p deletion. Physical mapping and DNA sequencing determined that the SRD minimally spans an estimated 729 kb. Genomic content and sequence analysis of the SRD identified 15 characterized, nine uncharacterized, and six predicted genes in the region. The RNA expression profiles of 21 of the genes were investigated in a variety of normal tissues. The SHREW1 and KCNAB2 genes both had tissue-restricted expression patterns, including expression in the nervous system. In addition, a novel gene (CHD5) with strong homology to proteins involved in chromatin remodeling was expressed mainly in neural tissues. Together, these results suggest that one or more genes involved in neuroblastoma tumorigenesis or tumor progression are likely contained within this region.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15829979     DOI: 10.1038/sj.onc.1208306

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  65 in total

Review 1.  Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins.

Authors:  Alea A Mills
Journal:  Nat Rev Cancer       Date:  2010-10       Impact factor: 60.716

Review 2.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

Review 3.  The Chd family of chromatin remodelers.

Authors:  Concetta G A Marfella; Anthony N Imbalzano
Journal:  Mutat Res       Date:  2007-01-21       Impact factor: 2.433

4.  1p36.32 rearrangements and the role of PI-PLC η2 in nervous tumours.

Authors:  Vincenza Rita Lo Vasco
Journal:  J Neurooncol       Date:  2010-09-29       Impact factor: 4.130

Review 5.  Chromatin remodeling and cancer, Part II: ATP-dependent chromatin remodeling.

Authors:  Gang G Wang; C David Allis; Ping Chi
Journal:  Trends Mol Med       Date:  2007-09-05       Impact factor: 11.951

6.  Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma.

Authors:  Annalisa Pezzolo; Elena Rossi; Stefania Gimelli; Federica Parodi; Francesca Negri; Massimo Conte; Angela Pistorio; Angela Sementa; Vito Pistoia; Orsetta Zuffardi; Claudio Gambini
Journal:  Neuro Oncol       Date:  2008-10-15       Impact factor: 12.300

7.  Missense variants in the chromatin remodeler CHD1 are associated with neurodevelopmental disability.

Authors:  Genay O Pilarowski; Hilary J Vernon; Carolyn D Applegate; Leandros Boukas; Megan T Cho; Christina A Gurnett; Paul J Benke; Erin Beaver; Jennifer M Heeley; Livija Medne; Ian D Krantz; Meron Azage; Dmitriy Niyazov; Lindsay B Henderson; Ingrid M Wentzensen; Berivan Baskin; Maria J Guillen Sacoto; Gregory D Bowman; Hans T Bjornsson
Journal:  J Med Genet       Date:  2017-09-02       Impact factor: 6.318

8.  Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform.

Authors:  John M Maris; George Hii; Craig A Gelfand; Shobha Varde; Peter S White; Eric Rappaport; Saul Surrey; Paolo Fortina
Journal:  Genome Res       Date:  2005-08       Impact factor: 9.043

9.  Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer.

Authors:  Kylie L Gorringe; David Yh Choong; Louise H Williams; Manasa Ramakrishna; Anita Sridhar; Wen Qiu; Jennifer L Bearfoot; Ian G Campbell
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

10.  A mutation in the mouse Chd2 chromatin remodeling enzyme results in a complex renal phenotype.

Authors:  Concetta G A Marfella; Nils Henninger; Scott E LeBlanc; Namrata Krishnan; David S Garlick; Lawrence B Holzman; Anthony N Imbalzano
Journal:  Kidney Blood Press Res       Date:  2009-01-14       Impact factor: 2.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.